Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Short Interest Update
by Teresa Graham · The Cerbat GemQuoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX – Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 94,409 shares, a growth of 1,136.7% from the March 15th total of 7,634 shares. Approximately 13.0% of the company’s shares are short sold. Based on an average daily volume of 351,130 shares, the short-interest ratio is presently 0.3 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.
Read Our Latest Report on Quoin Pharmaceuticals
Hedge Funds Weigh In On Quoin Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its stake in shares of Quoin Pharmaceuticals by 649.6% during the fourth quarter. GAMMA Investing LLC now owns 2,084 shares of the company’s stock valued at $30,000 after purchasing an additional 1,806 shares in the last quarter. Simplify Asset Management Inc. bought a new position in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $252,000. AIGH Capital Management LLC bought a new position in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $712,000. ADAR1 Capital Management LLC bought a new position in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $840,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $863,000. Institutional investors own 8.63% of the company’s stock.
Quoin Pharmaceuticals Price Performance
QNRX traded up $0.16 on Friday, hitting $5.90. The company had a trading volume of 9,118 shares, compared to its average volume of 245,722. Quoin Pharmaceuticals has a 52-week low of $5.01 and a 52-week high of $41.80. The stock has a fifty day simple moving average of $7.85 and a 200-day simple moving average of $11.03. The firm has a market capitalization of $4.95 million, a P/E ratio of -0.17 and a beta of 1.61.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last issued its quarterly earnings data on Friday, March 27th. The company reported ($14.80) EPS for the quarter, missing the consensus estimate of ($6.42) by ($8.38). Equities research analysts expect that Quoin Pharmaceuticals will post -2.05 earnings per share for the current fiscal year.
Quoin Pharmaceuticals Company Profile
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.